EGFR and non-small cell lung carcinoma: A recent case series by Peng et al. (Peng et al., 2021) showed that dacomitinib has potent efficacy against CNS metastasis in EGFR-positive NSCLC, with an ORR of 92.9% and a DCR of 100%.